ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Zingerone attenuates aluminum chloride/D-galactose-induced hippocampal neurotoxicity in mice: Modulation of oxidative stress, astrogliosis, cholinergic function, ATP hydrolysis, and neurotrophic signaling.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative disorders constitute a growing global health concern, with oxidative stress, cholinergic dysfunction, and compromised neuroplasticity identified as key pathological contributors. Zingerone, a bioactive phenolic compound from ginger (Zingiber officinale), possesses antioxidant and anti-inflammatory properties, but its neuroprotective capacity against combined aluminum chloride (AlCl₃) and D-galactose (D-Gal)-induced hippocampal neurotoxicity remains poorly characterized. This study evaluated the neuroprotective effects of zingerone (100 mg/kg) on spatial memory, brain antioxidant enzyme activities, acetylcholinesterase (AChE) activity, ATP hydrolysis and nitric oxide levels, together with hippocampal neuronal integrity, astrocytic reactivity, and brain-derived neurotrophic factor (BDNF) expression, in mice co-exposed to AlCl₃ and D-Gal, with donepezil (10 mg/kg) as the standard reference drug. Twenty male Swiss mice were randomly assigned to four groups (n = 5): Control, AlCl₃/D-Gal, AlCl₃/D-Gal + Zingerone, and AlCl₃/D-Gal + Donepezil. AlCl₃/D-Gal co-exposure significantly impaired Y-maze and Morris water maze performance, depleted catalase and superoxide dismutase activities, elevated AChE activity, ATP hydrolysis, and nitric oxide levels, reduced Nissl substance staining, increased glial fibrillary acidic protein (GFAP) immunoreactivity, and suppressed BDNF expression. Zingerone significantly reversed these deficits, producing significantly greater restoration of superoxide dismutase activity than donepezil (p < 0.01) and numerically greater catalase and BDNF responses, whereas donepezil produced greater AChE inhibition and a greater reduction in nitric oxide. These contrasting profiles indicate complementary mechanisms rather than therapeutic superiority of either agent, and provide a rationale for evaluating a zingerone-donepezil combination in future studies. These findings position zingerone as a promising multi-target neuroprotective agent.
Indexed as
Identifiers
42365121What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.